Clinical trial
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers…
NCT00172055 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00172055 |
|---|---|
| Title | Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy |
| Official title | Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer Prostate |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 218 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 6, 2017 |
| Countries | Belgium |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: